Form 4: Neurocrine Director Sells Shares Via 10b5-1 Plan

A Neurocrine Biosciences director exercised stock options and sold an equivalent number of shares for a significant profit under a pre-arranged trading plan.

Summary

• Kevin Charles Gorman, a Director at Neurocrine Biosciences Inc. (NBIX), executed a pre-planned transaction on August 7, 2025.
• Gorman acquired 106,322 shares of common stock by exercising non-qualified stock options at a price of $35.99 per share.
• Concurrently, he disposed of 106,322 shares of common stock at a weighted average sales price of $126.4111 per share, with prices ranging from $124.80 to $129.03.
• The disposition was conducted through a Rule 10b5-1 trading plan adopted on February 24, 2025, which cannot be amended or modified per issuer policy.
• Following these transactions, Gorman's direct beneficial ownership of common stock is 0 shares.
• An indirect beneficial ownership of 514,596 shares remains, held by the Gorman and Blais Family Trust, over which Dr. Gorman has voting and investment power.
• The exercised options were granted on February 5, 2016, vested in 48 equal monthly installments starting March 5, 2016, and were due to expire on February 5, 2026.

Sentiment

Score: 6

Explanation: While insider selling can be viewed negatively, the transaction was pre-planned under a 10b5-1 plan and involved the exercise of expiring options, which is a common and often expected event for executives managing their equity compensation. The significant profit realized is a positive for the insider.

Positives

• The director realized a substantial profit by exercising options at $35.99 and selling shares at an average of $126.41, demonstrating the value appreciation of the company's stock.
• The transaction was executed under a Rule 10b5-1 trading plan, indicating a pre-scheduled sale not based on immediate, non-public information.

Negatives

• The director's direct beneficial ownership of common stock is now 0 shares following the exercise and sale of the same quantity, which could be perceived as a reduction in direct insider alignment.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This transaction is an individual insider trading activity and does not directly reflect broader industry trends. However, the significant profit realized by the director highlights the growth and value creation within the biotechnology sector, particularly for companies with successful product pipelines like Neurocrine Biosciences.

Stakeholder Impact

• Shareholders: The sale by a director could be interpreted in various ways; however, the pre-planned nature mitigates concerns about a lack of confidence. The director retains significant indirect ownership.
• Employees: No direct impact mentioned.

Key Dates

Recommendation

The filing details a routine, pre-planned insider transaction (exercise and sell) by a director. While it reduces direct insider ownership, the transaction was not based on new information and the director retains substantial indirect holdings. This event alone does not provide new fundamental insights to warrant a change in investment recommendation, suggesting a 'hold' position is appropriate for existing investors.

Keywords

Neurocrine Biosciences, NBIX, SEC Form 4, Insider Trading, Stock Option Exercise, Share Sale, Rule 10b5-1 Plan, Director Transaction, Biotechnology, Pharmaceuticals